Achaogen (AKAO) Misses Q2 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 6, 2018 4:01 PM EDT-- ZEMDRIÂ (plazomicin), approved in the U.S. for the treatment of adults with complicated urinary tract infections --
-- Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first two weeks --
-- Conference call today at 4:30 p.m. Eastern Time --
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative... More
